1. Home
  2. BELFB vs VIR Comparison

BELFB vs VIR Comparison

Compare BELFB & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bel Fuse Inc. Class B

BELFB

Bel Fuse Inc. Class B

HOLD

Current Price

$209.79

Market Cap

2.5B

Sector

N/A

ML Signal

HOLD

Logo Vir Biotechnology Inc.

VIR

Vir Biotechnology Inc.

HOLD

Current Price

$9.47

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BELFB
VIR
Founded
1949
2016
Country
United States
United States
Employees
4964
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
1.5B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
BELFB
VIR
Price
$209.79
$9.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
8
Target Price
$174.25
$19.63
AVG Volume (30 Days)
135.8K
4.3M
Earning Date
01-01-0001
05-25-2026
Dividend Yield
0.14%
N/A
EPS Growth
N/A
17.49
EPS
N/A
N/A
Revenue
N/A
$68,556,000.00
Revenue This Year
$28.52
N/A
Revenue Next Year
$7.85
$925.73
P/E Ratio
$42.80
N/A
Revenue Growth
N/A
N/A
52 Week Low
$58.00
$4.16
52 Week High
$248.61
$10.91

Technical Indicators

Market Signals
Indicator
BELFB
VIR
Relative Strength Index (RSI) 49.59 57.65
Support Level $130.49 $4.64
Resistance Level $248.61 $10.91
Average True Range (ATR) 9.24 0.61
MACD -1.85 -0.05
Stochastic Oscillator 45.77 49.69

Price Performance

Historical Comparison
BELFB
VIR

About BELFB Bel Fuse Inc. Class B

Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

Share on Social Networks: